Office Partnerships Portfolios 
The Dermatology Digest
OCTOBER 28, 2024
“The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and biosimilar dermatology treatments,” says Kevin Ali, Chief Executive Officer of Organon, in a news release.
Spa Executive
OCTOBER 23, 2024
Travelers don’t just want to choose their own adventure – they want to maximize every moment of their time away,” said Chris Nassetta, president and chief executive officer, Hilton. These findings highlight new opportunities for us to innovate across our global portfolio and further enhance guests’ stays.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Dermatology Digest
DECEMBER 21, 2023
and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We We are extremely excited to expand our partnership with Evolus beyond the U.S.
The Dermatology Digest
DECEMBER 21, 2023
and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We We are extremely excited to expand our partnership with Evolus beyond the U.S.
Aesthetics Advisor
SEPTEMBER 15, 2023
It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement. Glenmark Pharmaceuticals has signed a partnership with Canadian company SaNOtize Research & Development Corp., Walter saw the potential application of nanobodies in modulating the behavior of eIF2B, and the partnership was soon made.
Expert insights. Personalized for you.
36 
Let's personalize your content